PharmaJet®, a global leader in needle-free injection technology, has announced the expansion of its innovative portfolio with the development of a new suite of proprietary, needle-free, self-injector pens. The prototypes of these subcutaneous (SC) injectors, designed for use in chronic disease and metabolic peptide self-injection markets, are currently undergoing early testing.
Self-injectable drug delivery systems offer important benefits to patients, caregivers, and healthcare systems. However, needle aversion and injection site pain remain major challenges that impact treatment adherence. PharmaJet’s needle-free injector pens aim to address these barriers by enhancing user comfort, reducing anxiety and pain during administration, and simplifying the injection process—particularly for patients with mobility limitations. Additionally, the reusable design of PharmaJet’s injectors is expected to offer a sustainable alternative to disposable devices that contribute to medical waste.
PharmaJet is a commercial-stage world leader in needle-free injection systems, with more than 12 million vaccine injections administered globally using its Tropis® intradermal Needle-Free Injection System. Published studies have shown that over 95% of caregivers prefer Tropis over conventional needle and syringe methods, while recipients report reduced pain (68%) and less soreness (69%). Recent research published in Vaccines also indicated that Tropis use improved immunization coverage and compliance rates compared to standard needle-based methods — a result that may extend to PharmaJet’s new needle-free pen injector experience.
PharmaJet’s extensive experience with reusable needle-free delivery systems has been integral to the development of its new SC injector pens now under evaluation.
"We are excited about the prospect of entering the pen injector market with the PharmaJet needle-free self-injector pens," said Wouter Latour, President and CEO of PharmaJet. "The PharmaJet devices are being designed to provide a superior user experience to a wide group of patients, while offering smart e-technology to track dosing and support patient compliance. We plan to reach out to industry in the coming months to build partnerships in the exponentially growing metabolic peptide segment and other markets where frequent injections are important."
Also Read